title: Reply to letter that comments on 'Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy'.
authors.affiliation: Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Germany.
authors.forename: R S
authors.initials: RS
authors.lastname: Pompe
authors.affiliation: Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Germany; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University Medical Center, Goettingen, Germany.
authors.forename: A O
authors.initials: AO
authors.lastname: von Bueren
authors.affiliation: Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Mynarek
authors.affiliation: Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Germany.
authors.forename: K
authors.initials: K
authors.lastname: von Hoff
authors.affiliation: Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Germany. Electronic address: s.rutkowski@uke.de.
authors.forename: S
authors.initials: S
authors.lastname: Rutkowski
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002528:Cerebellar Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000628:therapy*